Barclays
ELVN icon

Barclays’s Enliven Therapeutics ELVN Stock Holding History

Barclays’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
20,816
+8,986
+76% +$381K ﹤0.01% 2762
2026
Q1 		$464K Sell
11,830
-58,045
-83% -$1.61M ﹤0.01% 3233
2025
Q4 		$1.08M Sell
69,875
-814
-1% -$16.2K ﹤0.01% 3380
2025
Q3 		$1.45M Sell
70,689
-2,095
-3% -$42.2K ﹤0.01% 3124
2025
Q2 		$1.46M Buy
72,784
+22,427
+45% +$425K ﹤0.01% 3086
2025
Q1 		$991K Sell
50,357
-14,206
-22% -$306K ﹤0.01% 3109
2024
Q4 		$1.45M Buy
64,563
+8,346
+15% +$216K ﹤0.01% 3123
2024
Q3 		$1.44M Buy
56,217
+42,012
+296% +$973K ﹤0.01% 3112
2024
Q2 		$332K Sell
14,205
-12,031
-46% -$253K ﹤0.01% 3286
2024
Q1 		$461K Sell
26,236
-15,842
-38% -$243K ﹤0.01% 3641
2023
Q4 		$582K Buy
42,078
+28,449
+209% +$348K ﹤0.01% 3786
2023
Q3 		$186K Sell
13,629
-1,198
-8% -$20.2K ﹤0.01% 3335
2023
Q2 		$303K Buy
14,827
+7,600
+105% +$154K ﹤0.01% 3042
2023
Q1 		$158K Buy
+7,227
New +$147K ﹤0.01% 3928

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Barclays's ELVN Position: Q2 2026 in Review

Barclays increased its Enliven Therapeutics (ELVN) stake by 76% in Q2 2026, buying an estimated $381K and bringing the position to 20,816 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2762.

Barclays first reported a position in ELVN in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.46M in Q2 2025. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Barclays held 20,816 shares of Enliven Therapeutics worth $1.06M as of Q2 2026.
  • Barclays bought 8,986 Enliven Therapeutics shares in Q2 2026, an estimated $381K.
  • Enliven Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2762 holding.
  • Barclays first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Barclays's Enliven Therapeutics position peaked at $1.46M in Q2 2025.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.